Developing World Study for RotaTeq™ (V260-015)(COMPLETED)

Efficacy, Safety, and Immunogenicity of RotaTeq™ Among Infants in Asia and Africa

The purpose of the current study is to evaluate whether the vaccine is effective, well-tolerated and immunogenic among infants in developing countries.

Inclusion Criteria:

• Age 4 weeks through 12 weeks at Dose 1
• Parent able to understand study procedures and give consent

Exclusion Criteria:

• Clinical evidence of active gastrointestinal disease
• Subjects who are currently or expected to participate in other studies of investigational products during the 6 weeks after receiving the last dose of RotaTeq™/placebo